Dose Conversion: Trospium to Mirabegron
There is no direct dose equivalency between trospium 20 mg and mirabegron (Myrbetriq ER) because they work through completely different mechanisms—trospium is an antimuscarinic and mirabegron is a β3-adrenoceptor agonist—so start with mirabegron 25 mg once daily and titrate to 50 mg based on efficacy and tolerability.
Recommended Switching Strategy
When switching from trospium 20 mg to mirabegron:
- Discontinue trospium immediately (no washout period required based on real-world evidence)
- Start mirabegron 25 mg once daily 1
- Titrate to 50 mg after 4-8 weeks if symptom control is inadequate and the patient tolerates the 25 mg dose well
Rationale for This Approach
Why No Direct Equivalency Exists
Trospium blocks muscarinic receptors (M2 and M3) in the bladder, while mirabegron activates β3-adrenoceptors 2. These fundamentally different mechanisms mean there's no pharmacologic basis for dose-to-dose conversion. The 2019 AUA/SUFU guidelines treat antimuscarinics and β3-agonists as interchangeable second-line options without specifying dose equivalencies 3.
Evidence Supporting Direct Switching
A 2016 observational study of 282 patients (mean age 74.4 years) who switched directly from stable antimuscarinic therapy to mirabegron 25 mg demonstrated that 55.3% had better outcomes, 31.2% had similar outcomes, and only 10.3% had worse outcomes 4. Notably:
- Adverse events decreased from 24.1% to 12.8%
- Post-void residual urine decreased significantly
- 69.1% maintained mirabegron without resuming antimuscarinics for >3 months
- Higher baseline OAB symptom scores predicted better outcomes
Dosing Considerations
Start with 25 mg if the patient has:
- Age >65 years with concerns about detrusor contractility
- Benign prostatic hyperplasia (men)
- Central nervous system lesions
- Renal impairment (eGFR 15-29 mL/min/1.73m²) 1
Start with 50 mg if the patient:
- Is younger with robust voiding function
- Has failed multiple antimuscarinics
- Has no contraindications to the higher dose 5
Expected Outcomes and Monitoring
Efficacy Profile
Mirabegron demonstrates comparable efficacy to antimuscarinics for reducing:
A 2025 network meta-analysis found trospium 60 mg had the best efficacy for reducing micturitions, but mirabegron and vibegron were better tolerated regarding dry mouth and constipation 6.
Adverse Effect Profile Differences
Expect reduction in:
- Dry mouth (trospium: antimuscarinic effect vs. mirabegron: 3.9-6.1%) 1
- Constipation (significantly lower with mirabegron) 6, 7
- Cognitive concerns (trospium has lower CNS penetration than other antimuscarinics, but mirabegron avoids antimuscarinic effects entirely)
Monitor for new:
- Blood pressure elevation (mean increase ~3 mmHg in adults) 1
- Headache (2.9% with mirabegron 50 mg) 1
- Urinary tract infections (6.2-8.4%) 1
- Potential for urinary retention (though less than antimuscarinics) 1
Critical Pitfalls to Avoid
- Don't assume equivalent efficacy at any dose—individual response varies significantly; reassess at 4-8 weeks
- Don't overlook blood pressure monitoring—check BP at baseline and periodically, especially in patients with hypertension
- Don't forget food effects—counsel patients to take mirabegron with water on an empty stomach or with a light meal (high-fat meals reduce absorption by 35-60%) 2
- Don't ignore CYP2D6 interactions—mirabegron is a moderate CYP2D6 inhibitor; adjust doses of narrow therapeutic index drugs metabolized by this pathway 1
When Switching Fails
If symptom control remains inadequate after titrating to mirabegron 50 mg:
- Consider combination therapy: Add back a low-dose antimuscarinic (e.g., solifenacin 5 mg) to mirabegron 50 mg, which the 2019 AUA/SUFU guidelines support with Grade B evidence 3
- Alternative: Switch to a different antimuscarinic or consider third-line therapies (onabotulinumtoxinA, neuromodulation) 3
Recent evidence suggests combination therapy (solifenacin 5 mg + mirabegron 50 mg) provides additive benefits with acceptable tolerability for refractory cases 3.